Samantha Truex
Director/Board Member bij AVALO THERAPEUTICS, INC.
Profiel
Samantha Truex is currently the Director at Artios Pharma Ltd.
since 2022 and the Independent Director at Avalo Therapeutics, Inc. since 2024.
Previously, she held positions such as Chief Executive Officer at Quench Bio, Inc. and Upstream Bio, Inc. She also served as a Director at HotSpot Therapeutics, Inc. and Vice President-Corporate Development at Biogen, Inc. from 2010 to 2014.
Ms. Truex was the Chief Business Officer at Padlock Therapeutics, Inc. and the Chief Operating Officer at Synlogic Therapeutics from 2016 to 2017.
She started her career as a Director at Sanofi from 1998 to 2006.
Ms. Truex completed her undergraduate degree at Dartmouth College in 1992 and obtained an MBA from the Tuck School of Business at Dartmouth in 1995.
She also holds an undergraduate degree from the Thayer School of Engineering At Dartmouth, which she received in 1993.
Actieve functies van Samantha Truex
| Bedrijven | Functie | Begin |
|---|---|---|
| AVALO THERAPEUTICS, INC. | Director/Board Member | 28-03-2024 |
Artios Pharma Ltd.
 Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | Director/Board Member | 15-06-2022 |
Eerdere bekende functies van Samantha Truex
| Bedrijven | Functie | Einde |
|---|---|---|
| Synlogic Therapeutics | Chief Operating Officer | 30-06-2017 |
| BIOGEN INC. | Director/Board Member | 01-04-2010 |
| SANOFI | Director/Board Member | 31-12-2006 |
Upstream Bio, Inc.
 Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | Chief Executive Officer | - |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Consultant / Advisor | - |
Opleiding van Samantha Truex
| Dartmouth College | Undergraduate Degree |
| Tuck School of Business at Dartmouth | Masters Business Admin |
| Thayer School of Engineering At Dartmouth | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| BIOGEN INC. | Health Technology |
| SANOFI | Commercial Services |
| AVALO THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 7 |
|---|---|
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Padlock Therapeutics, Inc.
 Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | Health Technology |
Artios Pharma Ltd.
Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | Health Technology |
HotSpot Therapeutics, Inc.
 HotSpot Therapeutics, Inc. BiotechnologyHealth Technology HotSpot Therapeutics, Inc. develops new allosteric therapies with the ability to treat disease. The company was founded by Jonathan Montagu and Geraldine Harriman and is headquartered in Boston, MA. | Health Technology |
Quench Bio, Inc.
 Quench Bio, Inc. BiotechnologyHealth Technology Quench Bio, Inc. develops therapies targeting innate immune pathways to treat life-threatening auto-immune and inflammatory diseases. The company was founded by Mark J. Tebbe, Mike Nolan, and Arturo Zychlinsky and is headquartered in Cambridge, MA. | Health Technology |
| Synlogic Therapeutics | |
Upstream Bio, Inc.
Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | Commercial Services |
